C12N 2760/18811
Sendai virus
C12N2760/18811 (Sendai virus) appears on 123 US grants and 217 published applications in this corpus.
Search patents in C12N- Granted patents
- 123
- Published applications
- 217
- Assignees
- 113
- Inventors
- 390
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 3 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 3 | 0 |
| 2002 | 2 | 7 |
| 2003 | 3 | 12 |
| 2004 | 5 | 9 |
| 2005 | 2 | 9 |
| 2006 | 3 | 8 |
| 2007 | 3 | 4 |
| 2008 | 6 | 15 |
| 2009 | 2 | 9 |
| 2010 | 5 | 11 |
| 2011 | 2 | 7 |
| 2012 | 2 | 4 |
| 2013 | 2 | 3 |
| 2014 | 4 | 5 |
| 2015 | 3 | 4 |
| 2016 | 5 | 10 |
| 2017 | 3 | 6 |
| 2018 | 2 | 10 |
| 2019 | 6 | 11 |
| 2020 | 7 | 10 |
| 2021 | 9 | 7 |
| 2022 | 3 | 13 |
| 2023 | 3 | 12 |
| 2024 | 7 | 9 |
| 2025 | 10 | 17 |
| 2026 | 3 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/18841Use of virus, viral particle or viral elements as a vectorIndexing code66
- C12N 2760/18822New viral proteins or individual genes, new structural or functional aspects ofIndexing code36
- C12N 2760/18834Use of virus or viral component as vaccineIndexing code16
- C12N 2760/18851Methods of production or purification of viral materialIndexing code14
- C12N 2760/18821Viruses as suchIndexing code10
- C12N 2760/18832Use of virus as therapeutic agent, other than vaccineIndexing code9
- C12N 2760/18861Methods of inactivation or attenuationIndexing code8
- C12N 2760/18871Demonstrated in vivo effectIndexing code8
Recent patents
- Cell culture vessel and method for culturing cell5 May 2026US 12,618,037 B2Fanuc Corporation
- Method for producing induced pluripotent stem cells20 Jan 2026US 12,529,035 B1National University Corporation Kobe University
- Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent13 Jan 2026US 12,521,358 B2RaQualia Pharma Inc.
- Methods of using Zscan4 for rejuvenating human cells25 Nov 2025US 12,478,657 B2Elixirgen Therapeutics, Inc.
- Methods of using ZSCAN4 for rejuvenating human cells25 Nov 2025US 12,478,659 B2Elixirgen Therapeutics, Inc.
- Vaccine with reduced anti-vector antigenicity24 Sep 2026US 2026/0284178 A1
- Production method for induced pluripotent stem cells27 Aug 2026US 2026/0250638 A1Sekisui Chemical Co., Ltd.
- Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector27 Aug 2026US 2026/0250709 A1Repli-Tech Co., Ltd.
- Methods of using zscan4 for rejuvenating human cells11 Jun 2026US 2026/0158105 A1Elixirgen Therapeutics, Inc.
- Composition and Use Method Therefor14 May 2026US 2026/0131027 A1Nanjing Reju Therapeutics, Co., Ltd.
Most cited
By later US patents
- Infectious Sindbis virus vectors121US 5,217,879 AWashington University · 1993
- Process for the production of virus vaccine116US 4,659,569 AKabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo · 1987
- Antiviral agents73US 4,859,769 ASymbicom AB · 1989
- Reconstituting viral glycoproteins into large phospholipid vesicles62US 4,871,488 AAlbany Medical College of Union University · 1989
- Cochleate delivery vehicles33US 5,994,318 AAlbany Medical College · 1999